explore -WSS

explore

author：knowledge 2025-09-30 21:58:04 - browse：21

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout LOUD podcast, live from the STAT Breakthrough Summit East

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Delta passengers in Vegas fall sick while waiting on flight in triple

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

6 surprising facts about sugar

Wikipedia

explore

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

As demand for Covid shots wanes, Moderna seeks its next success

Diabetes management: Digital health tools fall short, study says

Hepatitis C has a cure — but many Americans still lack access to it

Asbestos ban is immediate, but health effects will linger for decades

After affirmative action ruling, medical educators look to 'holistic review'

6 surprising facts about sugar

After affirmative action ruling, medical educators look to 'holistic review'

A new ‘biological computer' targets cancer while sparing healthy cells

focus

Medical devices makers are asking for forgiveness, not permission

Texas board proposes rules on abortion law emergency exemption

How a Boston hospital is priming medical residents to use GPT

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Dementia risk linked to living in disadvantaged areas: Study

Caribou posts encouraging results on off

knowledge

Wikipedia

hotspot

entertainment